Abstract:HLA-G is a non-classical HLA class I molecule with immunomodulatory properties. It was initially described at the maternal-fetal interface, and it was later found that this molecule was constitutively expressed on certain immuneprivileged tissues, such as cornea, endothelial and erythroid precursors, and thymus. The immunosuppressive effect of HLA-G is exerted through the interaction with its cognate receptors, expressed on immunocompetent cells, like ILT2, expressed on NK, B, T cells and APCs; ILT4, on APCs; KIR, found on the surface of NK cells; and finally, the co-receptor CD8. Because of these immunomodulatory functions, HLA-G has been involved in several processes, amongst which organ transplantation, viral infections, cancer progression, and autoimmunity. HLA-G neo-expression on tumors has been recently described in several types of malignancies. In fact, tumor progression is tightly linked to the presence of the molecule, as it exerts its tolerogenic function, inhibiting the cells of the immune system and favoring tumor escape. Several polymorphisms in the 3’UTR region condition changes in HLA-G expression (14bp and +3142C/G, among others), which have been associated with both the development and outcome of patients with different tumor types. Also, in recent years, several studies have shown that HLA-G plays an important role in the control of autoimmune diseases. The ability of HLA-G to limit the progression of these diseases has been confirmed and, in fact, levels of the molecule and several of its polymorphisms have been associated with increased susceptibility to the development of autoimmune diseases, as well as increased disease severity. Thus, modulating HLA-G expression in target tissues of oncology patients or patients with autoimmune diseases may be potential therapeutic approaches to treat these pathological conditions.

Role of HLA-G in tumors and upon COVID-19 infection

Role of HLA-G in Viral Infections

The HLA-G immune checkpoint: a new immuno-stimulatory role for the α1-domain-deleted isoform

HLA-G Neo-Expression on Tumors

HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives

HLA-G neo-expression modifies genetic programs governing tumor cell lines

Soluble HLA-G, its diagnostic and prognostic value and potential target molecule for future therapy in cancer

Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges

HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease

Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma

HLA-G: A New Immune Checkpoint in Cancer?

HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance

Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy

HLA-G - evolvement from a trophoblast specific marker to a checkpoint molecule in cancer, a narrative review about the specific role in breast- and gynecological cancer

Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment

Human leukocyte antigen-G in gynaecological tumours

Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects

HLA-G can be transfered via trogocytosis from leukemic cells to T cells in chronic lymphocytic leukemia

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies

Features of HLA class I expression and its clinical relevance in SARS-CoV-2: What do we know so far?